12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

BeiGene, Merck KGaA deal

BeiGene granted Merck's Merck Serono S.A. unit exclusive, ex-Chinese rights to develop and commercialize BeiGene-290, a poly(ADP-ribose) polymerase (PARP) inhibitor in preclinical development for cancer. BeiGene...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >